title: What is optimal first-line treatment of unresectable or advanced BRAF-mutant melanoma?
authors.affiliation: Georgetown Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC.
authors.forename: Michael B
authors.initials: MB
authors.lastname: Atkins
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000066491:Clinical Decision-Making; D002986:Clinical Trials as Topic; D006801:Humans; D008545:Melanoma / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy*; D058990:Molecular Targeted Therapy; D009154:Mutation; D009367:Neoplasm Staging; D057285:Precision Medicine; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D048493:Proto-Oncogene Proteins B-raf